→The housing market fell by about 20%. (From Weiss Ratings)
Chemed Co. (NYSE:CHE – Get Rating) – Oppenheimer’s equity research analysts released Chemed’s first quarter 2024 EPS estimates in a research note issued to investors on Thursday, Jan. 19. . Oppenheimer analyst M. Wiederhorn expects the company to post earnings of $5.26 per share in the quarter. Chemed’s current consensus estimate for full-year earnings is $18.69 per share. Oppenheimer also estimates Chemed’s second-quarter 2024 earnings of $5.67 EPS, third-quarter 2024 earnings of $5.62 EPS, and fiscal 2025 earnings of $24.42 EPS.
A number of other brokerages have also recently commented on CHE. StockNews.com downgraded Chemed’s stock from a “strong buy” rating to a “buy” rating in a research report on Wednesday, November 9. In its report on Thursday, November 3, Royal Bank of Canada raised its price target on Chemed’s stock to $545.00 from $541.00, giving it an “outperform” rating.
Chemed Stock Performance
Chemed shares opened at $500.07 on Friday. The stock has a market cap of $7.44 billion, a price/earnings ratio of 29.06, a price/earnings ratio of 3.52, and a beta of 0.55. The business has a 50-day moving average of $507.57 and a 200-day moving average of $485.65. The company has a debt to equity ratio of 0.13, a current ratio of 0.67 and a quick ratio of 0.63. Chemed has a 12-month low of $430.16 and a 12-month high of $528.72.
Chemed (NYSE:CHE – Get Rating) last reported quarterly results on Monday, October 31. The company reported his earnings per share (EPS) for the quarter of $4.74, $0.13 above analyst consensus expectations of $4.61. Chemed’s net profit margin was 12.31% and return on equity was 44.29%. The business generated $526.47 million in revenue for the quarter, compared to consensus expectations of $527.05 million. During the same quarter last year, the company earned his EPS of $5.06. Revenue for this business decreased by 2.3% compared to the same quarter last year.
Chemed Announces Dividend
The company recently announced a quarterly dividend, which was paid out on Monday, December 5th. Shareholders of record on Monday, November 14 were awarded a dividend of $0.38 per share. This represents his $1.52 dividend and his 0.30% yield on an annual basis. The ex-dividend date was Thursday, November 10. Chemed’s payout percentage is currently 8.83%.
Insider trading on Chemed
In other news, CFO David Patrick Williams sold 1,000 shares of the company’s stock in a transaction that took place on Tuesday, November 8th. The shares sold for an average of $493.00 and the total transaction value was $493,000.00. Following the closing of the transaction, the Chief Financial Officer now directly owns 28,660 shares of the Company’s stock valued at approximately $14,129,380. The sale is disclosed in SEC filings available on his website. In related news, CFO David Patrick Williams sold 1,000 shares of his stock on Tuesday, November 8th. The shares were sold at an average price of $493.00 and the transaction totaled him $493,000.00. After the sale, the Chief Financial Officer now owns 28,660 shares of the company stock valued at $14,129,380. The transaction was disclosed in SEC filings accessible via this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of his Chemed stock in a deal on Thursday, November 3. The shares sold at an average price of $482.90 for a total transaction value of $965,800.00. After the sale, the CEO now owns 122,235 shares of the company stock valued at $59,027,281.50. Please see here for the disclosure of this sale. An insider said last quarter he sold 9,036 shares of company stock worth $4,444,780. A corporate insider owns his 4.03% stake in the company.
Hedge funds weigh heavily on Chemed
Many large investors are buying and selling stocks these days. Crossmark Global Holdings Inc. raised his Chemed stock position by 4.6% in the fourth quarter. Crossmark Global Holdings Inc. now owns 1,567 shares of the company worth $800,000 after he purchased an additional 69 shares during this period. Hanson & Doremus Investment Management increased its position in Chemed shares by 17.1% in the fourth quarter. Hanson & Doremus Investment Management now owns 4,200 shares of the company worth $2,144,000 after acquiring an additional 614 shares in the previous quarter. Ronald Blue Trust Inc. raised his stake in Chemed by 2.5% in the fourth quarter. Ronald Blue Trust Inc. now owns 1,548 shares worth $676,000 after acquiring an additional 38 shares during this period. Cooper Financial Group increased its stake in Chemed by 5.1% in the fourth quarter. Cooper Financial Group now owns 699 shares of the company, valued at $357,000, after acquiring an additional 34 shares in the previous quarter. Finally, Copeland Capital Management LLC increased its position in Chemed by 14.2% in the fourth quarter. Copeland Capital Management LLC now owns 157,854 shares of the company stock valued at $80,574,000 after purchasing an additional 19,685 shares during this period. Hedge funds and other institutional investors own 91.12% of the company’s shares.
Chemed Corp. is engaged in providing healthcare and maintenance services. It works through VITAS and Roto-Router segments. The VITAS segment provides hospice and palliative care services to patients through a network of physicians, registered nurses, home care paramedics, social workers, clergy and volunteers.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to firstname.lastname@example.org.
Listen to this before considering Chemed.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified 5 stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Chemed wasn’t on the list .
Chemed currently has a “buy” rating among analysts, but the top-rated analysts think these five stocks are the better buys.
See 5 stocks here